100 related articles for article (PubMed ID: 27701987)
1. Efficacy and safety of bladder hydrodistension for decreased bladder capacity induced by intravesical BCG therapy.
Numakura K; Tsuchiya N; Tsuruta H; Akihama S; Saito M; Inoue T; Narita S; Huang M; Satoh S; Habuchi T
Scand J Urol; 2016 Dec; 50(6):429-432. PubMed ID: 27701987
[TBL] [Abstract][Full Text] [Related]
2. A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy.
Mangiarotti B; Trinchieri A; Del Nero A; Montanari E
Arch Ital Urol Androl; 2008 Dec; 80(4):167-71. PubMed ID: 19235434
[TBL] [Abstract][Full Text] [Related]
3. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
4. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861.
Jakse G; Hall R; Bono A; Höltl W; Carpentier P; Spaander JP; van der Meijden AP; Sylvester R
Eur Urol; 2001 Aug; 40(2):144-50. PubMed ID: 11528191
[TBL] [Abstract][Full Text] [Related]
5. Chlorin e6-polyvinylpyrrolidone mediated photodynamic therapy--A potential bladder sparing option for high risk non-muscle invasive bladder cancer.
Lee LS; Thong PS; Olivo M; Chin WW; Ramaswamy B; Kho KW; Lim PL; Lau WK
Photodiagnosis Photodyn Ther; 2010 Dec; 7(4):213-20. PubMed ID: 21112542
[TBL] [Abstract][Full Text] [Related]
6. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
7. Intravesical bacille Calmette-Guérin (BCG) in immunologically compromised patients with bladder cancer.
Herr HW; Dalbagni G
BJU Int; 2013 May; 111(6):984-7. PubMed ID: 23351086
[TBL] [Abstract][Full Text] [Related]
8. Clinical study of bladder cancer: Proteinuria as a predictor of recurrence and efficacy of intravesical bacille Calmette-Guerin therapy.
Satoh A; Hanawa Y; Nakamura S
Int J Urol; 2004 Jul; 11(7):476-82. PubMed ID: 15242355
[TBL] [Abstract][Full Text] [Related]
9. [Prophylactic effect of inductive intravesical instillation of Bacillus Calmette-Guerin on postoperative recurrence of bladder cancer].
Yi SH; Ye G; Wang XW; Jin HS; Zhang YN; Yan ZL
Ai Zheng; 2008 Nov; 27(11):1208-11. PubMed ID: 19000455
[TBL] [Abstract][Full Text] [Related]
10. Conservative treatment of high grade superficial bladder tumours.
Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
[TBL] [Abstract][Full Text] [Related]
11. The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder.
Boorjian SA; Zhu F; Herr HW
BJU Int; 2010 Aug; 106(3):357-61. PubMed ID: 20002665
[TBL] [Abstract][Full Text] [Related]
12. [Intravesical radioimmunotherapy of carcinoma in situ of the urinary bladder after BCG failure].
Autenrieth ME; Horn T; Kurtz F; Nguyen K; Morgenstern A; Bruchertseifer F; Schwaiger M; Blechert M; Seidl C; Senekowitsch-Schmidtke R; Gschwend JE; Scheidhauer K
Urologe A; 2017 Jan; 56(1):40-43. PubMed ID: 27885456
[TBL] [Abstract][Full Text] [Related]
13. Treatment of BCG failures with intravesical BCG/Interferon: the University of Montreal experience.
Karakiewicz PI; Benayoun S; Lewinshtein DJ; Chun FK; Shahrour K; Perrotte P
Can J Urol; 2006 Aug; 13(4):3189-94. PubMed ID: 16952327
[TBL] [Abstract][Full Text] [Related]
14. [Non-muscle invasive bladder cancer].
Irani J
Rev Prat; 2014 Dec; 64(10):1382-5. PubMed ID: 25665317
[TBL] [Abstract][Full Text] [Related]
15. Reduction of Bladder Volume after BCG Immunotherapy.
Yang C; Lv Z; Li Y
Urol Int; 2021; 105(1-2):155-158. PubMed ID: 32882690
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
Yossepowitch O; Eggener SE; Bochner BH; Donat SM; Herr HW; Dalbagni G
J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
[TBL] [Abstract][Full Text] [Related]
17. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
Dinney CP; Greenberg RE; Steinberg GD
Urol Oncol; 2013 Nov; 31(8):1635-42. PubMed ID: 22575238
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment.
Kakiashvili DM; van Rhijn BW; Trottier G; Jewett MA; Fleshner NE; Finelli A; Azuero J; Bangma CH; Vajpeyi R; Alkhateeb S; Hanna S; Kostynsky A; Kuk C; Van Der Kwast TH; Zlotta AR
BJU Int; 2011 Feb; 107(4):540-6. PubMed ID: 21276177
[TBL] [Abstract][Full Text] [Related]
19. Long-term risk of progression of carcinoma in situ of the bladder and impact of bacille Calmette-Guérin immunotherapy on the outcome.
Zieger K; Jensen KM
Scand J Urol Nephrol; 2011 Dec; 45(6):411-8. PubMed ID: 21793636
[TBL] [Abstract][Full Text] [Related]
20. Chorioretinitis induced by intravesical Bacillus Calmette-Guérin (BCG) instillations for urinary bladder carcinoma.
Guex-Crosier Y; Chamot L; Zografos L
Klin Monbl Augenheilkd; 2003 Mar; 220(3):193-5. PubMed ID: 12664378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
